Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients

  • Authors:
    • Ondrej Zitka
    • Sylvie Skalickova
    • Jaromir Gumulec
    • Michal Masarik
    • Vojtech Adam
    • Jaromir Hubalek
    • Libuse Trnkova
    • Jarmila Kruseova
    • Tomas Eckschlager
    • Rene Kizek
  • View Affiliations

  • Published online on: September 21, 2012     https://doi.org/10.3892/ol.2012.931
  • Pages:1247-1253
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Oxidative stress causes profound alterations of various biological structures, including cellular membranes, lipids, proteins and nucleic acids, and it is involved in numerous malignancies. Reduced glutathione (GSH) is considered to be one of the most important scavengers of reactive oxygen species (ROS), and its ratio with oxidised glutathione (GSSG) may be used as a marker of oxidative stress. The main aim of this study was to determine GSH:GSSG ratio in the blood serum of paediatric cancer patients to use this ratio as a potential marker of oxidative stress. The whole procedure was optimised and the recoveries for both substances were greater than 80% under the optimised conditions. We analysed a group of paediatric patients (n=116) with various types of cancer, including neuroblastoma, anaplastic ependymoma, germ cell tumour, genital tract tumour, lymphadenopathy, rhabdomyosarcoma, nephroblastoma, Ewing's sarcoma, osteosarcoma, Hodgkin's lymphoma, medulloblastoma and retinoblastoma. We simultaneously determined the levels of reduced and oxidised glutathione, and thus, its ratio in the blood serum of the patients. The highest ratio was observed in retinoblastoma patients and the lowest in anaplastic ependymoma. We were able to distinguish between the diagnoses based on the results of the obtained GSH:GSSG ratio.

Introduction

Reduced glutathione (GSH), a ubiquitous tripeptide thiol, is a vital intracellular and extracellular protective antioxidant, which plays a number of key and/or crucial roles in the control of signalling processes, detoxifying certain xenobiotics and heavy metals, as well as other functions. It is a tripeptide composed of cysteine, glutamic acid and glycine. Intracellular and whole blood concentrations of GSH are in the milimolar range, while the plasma concentration is in the micromolar range and accounts for approximately 0.4% of total blood GSH (15). The GSH synthesis and metabolism pathway is shown in Fig. 1. GSH is synthesised in the cell by γ-glutamylcysteine synthetase (γ-GCS) and glutathione synthetase (6). The γ-GCS-catalysed formation of γ-glutamylcysteine is the first and rate-limiting step in de novo GSH synthesis and is feedback-inhibited by GSH, a mechanism that is central to the regulation of cellular GSH concentrations (7). Thus, cysteine is a rate-limiting substrate for de novo GSH synthesis (8).

Within cells, total GSH exists free and bound to proteins. Since the enzyme glutathione reductase, which reverts free glutathione from its oxidised form (GSSG) is constitutively active and inducible upon oxidative stress, free glutathione exists almost exclusively in its reduced form. The ratio of reduced to oxidised glutathione within cells is often used as a marker of cellular toxicity (912). Under normal conditions, the GSH redox couple is well-known to be present in mammalian cells in the concentration range of 1–10 mM. In a resting cell, the molar GSH:GSSG ratio exceeds 100:1, while in various models of oxidative stress, this ratio has been demonstrated to decrease to values of 10:1 and even 1:1 (13).

Oxidative stress is manifested by the excessive production of reactive oxygen species (ROS) in the face of insufficient or defective antioxidant defence systems. Oxidative stress causes profound alterations of various biological structures, including cellular membranes, lipids, proteins and nucleic acids. Oxidative stress is considered to be involved in ageing (1420) and in various diseases, including diabetes mellitus (2123), atherosclerosis (24,25), rheumatoid arthritis (2629), Alzheimer’s disease (3032), Parkinson’s disease (3335) and cancer (3644). There is an increasingly growing interest in identifying biomarkers for diseases, in which oxidative stress is involved (45).

For many years, GSH has been measured by several analytical methods. In particular, high performance liquid chromatography (HPLC) with various detection techniques including ultraviolet (UV) absorbance and fluorescence detection, mass spectrometry and/or electrochemical detection (ED) are commonly used for determination of GSH and GSSG concentrations (4649). Each method has its advantages and limitations and may serve a particular need in analysis (50). ED is an attractive alternative method for electroactive species detection, due to its inherent advantages of simplicity, ease of miniaturisation, high sensitivity and relatively low cost. The aim of this study was to determine the GSH:GSSG ratio in the blood serum of paediatric cancer patients to use this ratio as a potential marker of oxidative stress. For determination of the GSH:GSSG ratio, HPLC-ED was optimised and used.

Material and methods

Chemicals and pH measurements

GSH, GSSG and trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). HPLC-grade methanol (>99.9%; v/v) was obtained from Merck KGaA (Darmstadt, Germany). Other chemicals were purchased from Sigma-Aldrich unless otherwise stated. Stock standard solutions of the thiols (1 mg.ml−1) were prepared with ACS water (Sigma-Aldrich) and stored at −20°C in the dark. Working standard solutions were prepared daily by diluting the stock solutions. All solutions were filtered through 0.45-μm nylon filter discs (Millipore, Billerica, MA, USA) prior to HPLC analysis. The pH value was measured using WTW inoLab Level 3 with terminal Level 3 (WTW GmbH, Weilheim, Germany).

HPLC-ED analysis

The HPLC-ED system consists of two chromatographic pumps (Model 582; ESA, Inc., Chelmsford, MA, USA; working range 0.001–9.999 ml/min), a chromatographic column with reverse phase Zorbax eclipse AAA C18 (Agilent Technologies, Inc., Santa Clara, CA, USA; 150x4.6 mm; 3.5-μm particles) and a twelve-channel CoulArray electrochemical detector (Model 5600A; ESA, Inc.). The detector consists of three flow analytical chambers (Model 6210; ESA, Inc.). Each chamber contains four analytical cells and one analytical cell contains two referent (hydrogen-palladium), as well as two counters and porous graphite working electrodes. The ED is situated in the thermostated control module. A 20 μl sample was injected using an autosampler (Model 542; ESA, Inc.), which has thermostated space for the column. The column was termostated at 35°C. Other conditions were optimised and are described later.

Determination of recovery in real samples

Recovery of GSH and GSSG were evaluated with homogenates spiked with standards according to Causon (50). Prior to extraction, 100 μl GSH and GSSG was added to the blood serum homogenate. Homogenates were blindly assayed and the concentration of GSH and GSSG was derived from the calibration curves. The spiking of GSH and GSSG was determined as a standard measured in the absence of real sample. Accuracy was evaluated by comparing the estimated concentration with the known concentrations of both thiols.

Human blood serum

Blood samples were obtained from 116 children hospitalised at the Department of Paediatric Haematology and Oncology (Faculty Hospital Motol, Prague, Czech Republic) with newly diagnosed solid tumours of neuroblastoma (n=27), nephroblastoma (n=8), anaplastic ependymoma (n=4), Ewing’s sarcoma (n=9), germ cell tumour (n=4), osteosarcoma (n=16), tumour of the genital tract (n=6), Hodgkin’s lymphoma (n=16), lymphadenopathy (n=3), medulloblastoma (n=15), rhabdomyosarcoma (n=4) and retinoblastoma (n=4). The study was approved by the ethics committee of Faculty Hospital Motol, Prague, Czech Republic. Written informed patient consent was obtained from the patients. Subjects ranged between 1 and 10 years of age. The blood samples were collected before chemotherapy and radiotherapy. Serum was separated by centrifugation at 4,000 × g for 10 min (Model 5402; Eppendorf AG, Hamburg, Germany), and the samples were stored at −80°C until assayed. When required, the denatured samples were centrifuged at 15,000 x g at 4°C for 30 min (Model 5402; Eppendorf AG) and directly analysed using an optimised HPLC-ED method.

Descriptive statistics

Data were processed using Microsoft Excel (USA). Results are expressed as mean ± standard deviation (SD) unless otherwise stated. The detection limits [3 signal/noise (S/N)] were calculated according to Long and Winefordner (51), while N was expressed as the SD of noise determined in the signal domain unless otherwise noted.

Results

Optimisation of HPLC-ED method

Primarily, it was necessary to optimise the separation and subsequent ED in order to achieve the required accuracy and sensitivity for the determination of GSH and GSSG in real blood serum samples. Therefore, we focused on studying the influence of flow rate, concentration of components of the mobile phase, elution and applied potential of the working electrodes on GSH and GSSG signals.

Flow rate

The mobile phase flow rate is an important parameter influencing the electrochemical response of the detector. When using a chromatographic column Zorbax Eclipse AAA, optimum mobile phase flow rate was 1 ml/min at pressures of 130 bars. Additionally, we identified that if the flow >1 ml/min, the responses of GSH and GSSG decreased by >10%. This is probably caused by reducing the time-concentration of the analyte on the electrode surface. Even with a lower flow rate, a decreased signal occurred compared with the maximum, but the total peak area remained the same with a tolerance of 7%. Although a lower flow rate may not be significantly affected by resolution, it may extend the period of separation, which is critical for analysing a large number of clinical samples. Therefore, we decided to use 1 ml/min as the optimum flow rate of the mobile phase.

Influence of methanol on ED

Achieving an optimal resolution is crucial for simultaneous separation of analytes. In order to separate all determined substances in the system with reversed-phase, a gradient with the increasing content of organic solvent is required. Since the electrochemical determination of substances contained in the sample requires the presence of an electrolyte, we examined the effect of the organic solvent (methanol) on the electrochemical response of analytes. We identified that 15% content of methanol in the mobile phase, which is the polar component of the mobile phase composed also from 80 mM TFA, lead to more than 50% decrease in GSH signal. A marked decline of GSSG signal was also observed. The best ratio of 80 mM TFA and methanol in the mobile phase was 99:1 (v/v).

Optimisation of gradient

If GSH and GSSG were separated by isocratic elution where the ratio of TFA and methanol was 99:1 (v/v), it would be the most sensitive, but the retention times of the separated substances would be too high. A significant tailing of peaks was observed during the elution of compounds with higher retention under these conditions. Therefore, we optimised the increasing content of methanol with respect to the sensitivity of the analysis. Based on the optimisation steps, the mobile phase, which consisted of (A) 80 mM TFA and (B) 100% methanol, was used for separation and detection of GSH and GSSG. Compounds were eluted by following an increasing linear gradient: 0–1 min (3% B), 1–2 min (10% B), 2–5 min (30% B) and 15–16 min (98% B). Flow rate of the mobile phase was 1 ml/min, and the time of one analysis inducing column regeneration was 20 min.

ED

Sensitivity of the electrochemical detector may be more influenced by factors including the type of electrolyte in the mobile phase, concentration, pH and, in particular, applied potential. TFA was used as an ion-pair reagent, which provides the best separation conditions in the parameters mentioned above, and at a concentration of 80 mM it is also an extremely suitable electrolyte for the detection of thiols. We further studied the effect of the applied potential on the working electrode set separately for GSH and GSSG, which were designed for hydrodynamic voltammogram (HDV). Tested potentials were 100, 200, 300, 400, 500, 600, 700, 800, 900 and 1,000 mV. The responses detected at 100 mV were negligible; however, when the potential reached 300 mV, detectable signals for GSH and GSSG were observed. While the GSH signal markedly increased from 600 mV, the GSSG signal markedly increased from 700 mV. This is probably due to the requirement for greater power for partial dissociation of the -S-S- group on the surface of the working electrode, in comparison to the relatively easily accessible -SH moiety of GSH. We observed the highest signals for both compounds when a potential of 900–1,000 mV was applied, which is evident from the HDVs showed in Fig. 2A. Based on the HDV results we were able to evaluate that the best glutathione detection was achieved when a potential of 900 mV was applied to the working electrodes.

Calibration parameters

After identifying the optimal separation and detection conditions, the calibration curves for GSH and GSSG were measured within the concentration range of 0.2–100 μM. Overlay of HPL chromatograms is shown in Fig. 2B, and the calibration curves are shown in Fig. 2C. The obtained dependences were strictly linear with R2=0.9997 for GSH and R2=0.9936 for GSSG. Detection limits (3 S/N) were estimated with nanomolar subunits for both substances of interest.

Sample pretreatment for GSH:GSSG ratio determination

Prior to chromatographic analysis, precipitation of proteins with TFA to avoid excessive clogging of filters and precolumns, which protect the separation column from contaminations, was required. The proteins may interfere with detected substances and the obtained chromatograms may be extremely difficult to analyse. The denatured sample was than centrifuged and the resulting supernatant was directly injected to the chromatographic column. To ensure the lowest possible loss of target compounds during sample preparation it was necessary to examine several factors of a sample treatment, which could affect the overall recovery of GSH and GSSG.

Stability of GSH

Given that the formation of complexes may be faster under certain conditions (pH and ionic strength), we decided to investigate the possibility of GSH complex formation in the solution used for isolation. The formation of the complex was determined via a decrease in the GSH peak. Primarily, we examined the effect of molar concentrations of phosphate buffer (0.1, 0.5, 1, 5, 10 and 20 mM; pH 7.5) on the GSH (50 μg/ml) signal. These samples were left following preparation at room temperature, and were analysed by HPLC at time 0, 130 (2.2 h) and 260 min (4.3 h). Based on the results obtained, higher concentrations of buffer caused a decreasing GSH signal, i.e. concentration; thus, 20 mM phosphate buffer caused the highest decrease of glutathione concentration. It is clear that the greatest stability of GSH was observed in samples prepared in the presence of low concentrations of phosphate buffer.

Specifically, the lowest loss of glutathione occurred at the applied concentrations of 0.1–1 mM (Fig. 3A). These results clearly demonstrated that lower concentrations of phosphate buffer contribute to the stability of the sample. Therefore, for further experiments we used 1 mM phosphate buffer (pH 7.5).

Influence of various chemicals on GSH:GSSG ratio

To determine the extent of oxidative stress by glutathione it is necessary to know the ratio of GSH:GSSG. Therefore, we were aimed to determine whether TFA, which is normally added to the sample due to deproteination, could have an effect on GSSG level. We also studied the effect of adding the reducing agent tris(2-carboxylethyl)phosphine (TCEP), which may markedly influence the ratio of GSH:GSSG. Studies on TFA and TCEP were conducted in buffer and blood sera, and all variants were prepared with the same concentration of 50 μg/ml GSH and 5 μg/ml GSSG. Samples were prepared in the presence of (i) 1 mM phosphate buffer (pH 7.5), (ii) 1 mM phosphate buffer (pH 7.5) with 5% TFA (v/v), and (iii) 1 mM phosphate buffer (pH 7.5) with 1 mM TCEP. To be able to assess the influence of the matrix, samples of blood serum were prepared in the same way. All samples were vortexed for 1 min and immediately analysed by HPLC following preparation. The GSH:GSSG ratio was determined, where the ratio of 10 was taken as a control. In the case of using 5% TFA, ±7% change from control was determined in variants of buffer and serum (Fig. 3B). The results reveal that TFA did not affect the ratio of GSH:GSSG. However, following the addition of TCEP, there was a significant increase in the ratio to 38 and 48 in the buffer and blood serum, respectively. TCEP reduced the majority of GSSG to GSH, which was the reason for the significant increase of the GSH:GSSG ratio. In the case of blood serum, the ratio was even higher compared with buffer. This phenomenon may be explained by the involvement of the biological matrix in a non-specific reaction of the complexes or the presence of certain concentrations of glutathione bound to the matrix constituents. These results clearly indicate that TCEP reduces GSSG back to GSH, which could be used to determine the total amount of glutathione.

Recovery of pretreatment

Recovery estimation for sample preparation and analysis for a sample of blood serum using an optimised separation method was conducted by adding 10 μg/ ml GSH and 10 μg/ml GSSG prior to precipitation with 5% TFA and subsequent centrifugation. A sample with a GSH:GSSG ratio of 2.8 was used for determining recovery. The resulting recoveries are indicated in Table I. A recovery estimation of 83 and 89% for GSH and GSSG, respectively, clearly follows from the results previously obtained. GSH recovery can be associated with the imperfect protection of free-SH groups of glutathione, which can interact with the remains of biological matrices, and thus reduce the total concentration of free GSH during the preparation of the samples.

Table I.

Recovery of GSH and GSSG for blood serum sample analysis (n=5).

Table I.

Recovery of GSH and GSSG for blood serum sample analysis (n=5).

Substance of interestHomogenate (μg/ml)Spiking (μg/ml)Homogenate + spiking (μg/ml)Recovery (%)
GSH54±650±586±1083
GSSG25±410±231±389

[i] GSH, reduced gluthione; GSSG, oxidised gluthione.

Determination of GSH:GSSG ratio in paediatric patients

The antioxidant function of GSH is primarily due to its involvement in enzymatic pathways that cells have developed against ROS. The most important pathway involves glutathione peroxidase (GPx) and glutathione reductase (GR). GPx catalyses the reduction of hydrogen peroxide, which is produced by superoxide dismutase (SOD) through the dismutation of superoxide anions or organic hydroperoxides. GSH and GSH-dependent enzymes act in cooperation to scavenge ROS and/or neutralise their toxic oxidising effect. These systems act at the same time and in cooperation to protect the human body from ROS. Under oxidative stress conditions, GSH is oxidised to GSSG; thus, the GSH:GSSG ratio is altered.

Discussion

The GSH:GSSG ratio may be used as a marker of oxidative stress, which arises due to various malignancies. Using the optimised method, we were able to analyse real samples of paediatric patients (Fig. 4A). GSH and GSSG concentrations identified in each sample were recalculated to recovery, and based on these values, the GSH:GSSG ratios were given. The lowest number of patients in a group (n=3) were diagnosed with lymphadenopathy and the highest number (n=27) were diagnosed with neuroblastoma. Average values of GSH:GSSG ratio are demonstrated in Fig. 4B. The results reveal that the lowest redox status, which is given by the GSH:GSSG ratio of 1.4, was identified in patients diagnosed with ependymoma anaplastic, and the second lowest ratio of 1.5 was identified in patients diagnosed with genital tract tumour. The average values of both groups of patients also had a large relative standard deviation (RSD) of 50.3 and 41.5%, respectively. The lowest RSDs were identified in lymphadenopathy and rhabdomyosarcoma patients with a higher GSH:GSSG ratio of 4.0 and 3.5, where RSDs were 18.4 and 22.1, respectively. Additionally, the lowest oxidative damage, expressed as a GSH:GSSG ratio of 5.2, was revealed in retinoblastoma patients.

Acknowledgements

Financial support from NANOSEMED GA AV (Grant No. KAN208130801), NanoBioTECell GA CR (Grant No. 102/11/1068), CEITEC (Grant No. CZ.1.05/1.1.00/02.0068) and and the Project for Conceptual Development of Research Organization (00064203) is gratefully acknowledged.

References

1. 

P LochmanT AdamD FriedeckyE HlidkovaZ SkopkovaHigh-throughput capillary electrophoretic method for determination of total aminothiols in plasma and urineElectrophoresis2412001207200310.1002/elps.20039015412707912

2. 

F MicheletR GueguenP LeroyM WellmanA NicolasG SiestBlood and plasma glutathione measured in healthy-subjects by HPLC: relation to sex, aging, biological variables, and life habitsClin Chem411509151719957586526

3. 

A PastoreR MassoudC MottiFully automated assay for total homocysteine, cysteine, cysteinylglycine, glutathione, cysteamine, and 2-mercaptopropionylglycine in plasma and urineClin Chem448258321998

4. 

JP RichieL SkowronskiP AbrahamY LeutzingerBlood glutathione concentrations in a large-scale human studyClin Chem42647019968565235

5. 

M SheaS HowellHigh-performance liquid chromatographic measurement of exogenous thiosulfate in urine and plasmaAnal Biochem140589594198410.1016/0003-2697(84)90211-26486442

6. 

A MeisterSS TateGlutathione and related gamma-glutamyl compounds: biosynthesis and utilizationAnnu Rev Biochem45559604197610.1146/annurev.bi.45.070176.003015

7. 

OW GriffithA MeisterPotent and specific-inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)J Biol Chem25475587560197938242

8. 

A MeisterME AndersonO HwangIntracellular cysteine and glutathione delivery systemsJ Am Coll Nutr5137151198610.1080/07315724.1986.107201213722629

9. 

S CarelliA CeriottiA CabibboG FassinaM RuvoR SitiaCysteine and glutathione secretion in response to protein disulfide bond formation in the ERScience27716811684199710.1126/science.277.5332.16819287224

10. 

R LocignoV CastronovoReduced glutathione system: role in cancer development, prevention and treatment (review)Int J Oncol19221236200111445833

11. 

G NoctorCH FoyerAscorbate and glutathione: keeping active oxygen under controlAnnu Rev Plant Physiol Mol Biol49249279199810.1146/annurev.arplant.49.1.24915012235

12. 

DM TownsendKD TewH TapieroThe importance of glutathione in human diseaseBiomed Pharmacother57145155200310.1016/S0753-3322(03)00043-X12818476

13. 

YC ChaiSS AshrafK RokutanRB Johnston JrJA ThomasS-thiolation of individual human neutrophil proteins including actin by stimulation of the respiratory burst: evidence against a role for glutathione disulfideArch Biochem Biophys310273281199410.1006/abbi.1994.1167

14. 

L ArranzC FernándezA RodríguezJM RiberaM De la FuenteThe glutathione precursor N-acetylcysteine improves immune function in postmenopausal womenFree Radic Biol Med4512521262200810.1016/j.freeradbiomed.2008.07.01418694818

15. 

K HashimotoW TakasakiT YamotoS ManabeI SatoS TsudaEffect of glutathione (GSH) depletion on DNA damage and blood chemistry in aged and young ratsJ Toxicol Sci33421429200810.2131/jts.33.42118827442

16. 

R ChristonRB HalouiG DurandDietary polyunsaturated fatty acids and aging modulate glutathione-related antioxidants in rat liverJ Nutr1253062307019957500185

17. 

P MaherThe effects of stress and aging on glutathione metabolismAgeing Res Rev4288314200510.1016/j.arr.2005.02.00515936251

18. 

I RebrinAC BayneRJ MockettWC OrrRS SohalFree aminothiols, glutathione redox state and protein mixed disulphides in aging Drosophila melanogasterBiochem J382131136200410.1042/BJ2004050615142037

19. 

I RebrinRS SohalPro-oxidant shift in glutathione redox state during agingAdv Drug Deliv Rev6015451552200810.1016/j.addr.2008.06.00118652861

20. 

PS SamiecC Drews-BotschEW FlaggGlutathione in human plasma: decline in association with aging, age-related macular degeneration, and diabetesFree Radic Biol Med24699704199810.1016/S0891-5849(97)00286-49586798

21. 

A CerieloE MotzA CavarapeHyperglycemia counterbalances the antihypertensive effect of glutathione in diabetic patients: evidence linking hypertension and glycemia through the oxidative stress in diabetes mellitusJ Diabetes Complications11250255199710.1016/S1056-8727(97)00021-4

22. 

Y DincerT AkcayZ AlademirH IlkovaEffect of oxidative stress on glutathione pathway in red blood cells from patients with insulin-dependent diabetes mellitusMetabolism5113601362200210.1053/meta.2002.3519212370859

23. 

K YoshidaJ HirokawaS TagamiY KawakamiY UrataT KondoWeakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and effluxDiabetologia38201210199510.1007/BF00400095

24. 

P MarguttiP MatarreseF ContiAutoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosisBlood11145594570200810.1182/blood-2007-05-09282517993611

25. 

SS SignorelliS NeriL Di PinoOxidative stress and endothelial damage in patients with asymptomatic carotid atherosclerosisClin Exp Med1912200110.1007/s10238-001-8002-711467406

26. 

MQ HassanRA HadiZS Al-RawiVA PadronSJ StohsThe glutathione defense system in the pathogenesis of rheumatoid arthritisJ Appl Toxicol216973200110.1002/jat.73611180282

27. 

JH Pedersen-LaneRB ZurierDA LawrenceAnalysis of the thiol status of peripheral blood leukocytes in rheumatoid arthritis patientsJ Leukoc Biol81934941200710.1189/jlb.080653317210617

28. 

A SevenS GuzelM AslanV HamuryudanLipid, protein, DNA oxidation and antioxidant status in rheumatoid arthritisClin Biochem41538543200810.1016/j.clinbiochem.2008.01.02918313405

29. 

E KarelsonR MahlapuuM ZilmerU SoometsN BogdanovicU LangelPossible signaling by glutathione and its novel analogue through potent stimulation of frontocortical G proteins in normal aging and in Alzheimer’s diseaseCell Signaling, Transcription, and Translation as Therapeutic Targets973M DiederichNew York Academy of SciencesNew York537540200212485924

30. 

HL LiuH WangS ShenviTM HagenRM LiuGlutathione metabolism during aging and in Alzheimer diseaseStrategies for Engineered Negligible Senescence: Why Genuine Control of Aging May Be Foreseeable1019ADN De GreyNew York Academy of SciencesNew York346349200415247041

31. 

R ResendePI MoreiraT ProencaBrain oxidative stress in a triple-transgenic mouse model of Alzheimer diseaseFree Radic Biol Med4420512057200810.1016/j.freeradbiomed.2008.03.01218423383

32. 

AE LangThe progression of Parkinson disease: a hypothesisNeurology68948952200710.1212/01.wnl.0000257110.91041.5d17372132

33. 

MB SpinaG CohenDopamine turnover and glutathione oxidation: implications for Parkinson diseaseProc Natl Acad Sci USA8613981400198910.1073/pnas.86.4.13982919185

34. 

N YamamotoH SawadaY IzumiProteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson diseaseJ Biol Chem28243644372200710.1074/jbc.M60371220017158454

35. 

SC BarrancoRR PerryME DurmRelationship between colorectal cancer glutathione levels and patient survival: early resultsDis Colon Rectum4311331140200010.1007/BF0223656210950013

36. 

J KigawaY MinagawaY KanamoriGlutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancerCancer82697702199810.1002/(SICI)1097-0142(19980215)82:4%3C697::AID-CNCR12%3E3.0.CO;2-T9477102

37. 

A KumarS SharmaCS PundirA SharmaDecreased plasma glutathione in cancer of the uterine cervixCancer Lett94107111199510.1016/0304-3835(95)03832-H7621438

38. 

DYK WongYL HsiaoCK PoonGlutathione concentration in oral cancer tissuesCancer Lett81111116199410.1016/0304-3835(94)90191-0

39. 

CC YehMF HouSH WuA study of glutathione status in the blood and tissues of patients with breast cancerCell Biochem Funct24555559200610.1002/cbf.127516142688

40. 

W DrogeFree radicals in the physiological control of cell functionPhysiol Rev824795200211773609

41. 

JD HayesDJ PulfordThe glutathione S-Transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistanceCrit Rev Biochem Mol Biol30445600199510.3109/104092395090834918770536

42. 

M ValkoCJ RhodesJ MoncolM IzakovicM MazurFree radicals, metals and antioxidants in oxidative stress-induced cancerChem Biol Interact160140200610.1016/j.cbi.2005.12.00916430879

43. 

JD HayesLI McLellanGlutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stressFree Radic Res31273300199910.1080/10715769900300851

44. 

I Dalle-DonneR RossiR ColomboD GiustariniA MilzaniBiomarkers of oxidative damage in human diseaseClin Chem52601623200610.1373/clinchem.2005.06140816484333

45. 

B KlejdusJ ZehnálekV AdamSub-picomole high-performance liquid chromatographic/mass spectrometric determination of glutathione in the maize (Zea mays L.) kernels exposed to cadmiumAnal Chim Acta520117124200410.1016/j.aca.2004.02.060

46. 

D PotesilJ PetrlovaV AdamSimultaneous femtomole determination of cysteine, reduced and oxidized glutathione, and phytochelatin in maize (Zea mays L.) kernels using high-performance liquid chromatography with electrochemical detectionJ Chromatogr A1084134144200510.1016/j.chroma.2005.06.019

47. 

J PetrlovaR MikelovaK StejskalSimultaneous determination of eight biologically active thiol compounds using gradient elution-liquid chromatography with Coul-Array detectionJ Sep Sci2911661173200610.1002/jssc.200500425

48. 

O ZitkaD HuskaS KrizkovaAn investigation of glutathione-platinum(II) interactions by means of the flow injection analysis using glassy carbon electrodeSensors712561270200710.3390/s7071256

49. 

Y IwasakiY SaitoY NakanoChromatographic and mass spectrometric analysis of glutathione in biological samplesJ Chromatogr B Analyt Biomed Life Sci87733093317200910.1016/j.jchromb.2009.07.00119620027

50. 

R CausonValidation of chromatographic methods in biomedical analysis - viewpoint and discussionJ Chromatogr B689175180199710.1016/S0378-4347(96)00297-69061492

Related Articles

Journal Cover

December 2012
Volume 4 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zitka, O., Skalickova, S., Gumulec, J., Masarik, M., Adam, V., Hubalek, J. ... Kizek, R. (2012). Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients. Oncology Letters, 4, 1247-1253. https://doi.org/10.3892/ol.2012.931
MLA
Zitka, O., Skalickova, S., Gumulec, J., Masarik, M., Adam, V., Hubalek, J., Trnkova, L., Kruseova, J., Eckschlager, T., Kizek, R."Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients". Oncology Letters 4.6 (2012): 1247-1253.
Chicago
Zitka, O., Skalickova, S., Gumulec, J., Masarik, M., Adam, V., Hubalek, J., Trnkova, L., Kruseova, J., Eckschlager, T., Kizek, R."Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients". Oncology Letters 4, no. 6 (2012): 1247-1253. https://doi.org/10.3892/ol.2012.931